Patient-derived Organoids of Lung Cancer to Test Drug Response

Last updated: May 31, 2024
Sponsor: University Hospital, Geneva
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lung Cancer

Non-small Cell Lung Cancer

Cancer

Treatment

Lung tumor resection

Clinical Study ID

NCT03979170
2018-02395
  • Ages > 18
  • All Genders

Study Summary

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically proven lung cancer

  • Age ≥ 18

  • Written informed and signed consent

  • Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

Exclusion

Exclusion Criteria:

  • Less than 18 years of age

  • Not able to give informed consent (language, intellectual capacities, etc.)

  • Not accessible to biopsy and/or surgery sample

  • Not enough lung tissue for a histological analysis or the remaining lung tissue isnot enough to perform a routine pathological analysis.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Lung tumor resection
Phase:
Study Start date:
April 01, 2019
Estimated Completion Date:
December 30, 2029

Study Description

The aim of the project is to use a combination of patient-derived organoid models:

  • To amplify tumour tissue to obtain enough material for genomic and histological analysis

  • to characterize the lung cancer sub-type

  • To predict treatment (non)response.

The following points will be addressed:

  1. First, the investigators plan to establish and characterize formation of organoids from biopsies of patients with lung cancer: in spheroids, in the 3D cellular model OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM). Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared to the original tumour.

  2. Second, the investigators will test the chemoresponse (chemosensitivity and chemoresistance) of organoids to anti-cancer treatment.

Connect with a study center

  • Geneva University Hospitals

    Geneva, 1205
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.